May is Mental Health Awareness Month. For reimbursement directors, the development worth tracking this month is that trauma screening has become a claim-level payment issue, and the payment mechanism that started in California now operates in two more states with different administrative architectures.

For reimbursement directors outside California, this matters in three specific ways: recurring revenue your affiliated providers may already be eligible for, contract implications when your state follows, and commercial payer ripple effects that historically arrive ahead of analogous federal action. The rest of this piece works through the evidence, then returns to those implications and what to do about them.

What California built

In January 2020, California’s Medicaid program (Medi-Cal) began paying providers $29 per screen for screening children and adults for Adverse Childhood Experiences using a standardized tool. Two HCPCS codes — G9919 for a screen indicating high risk for toxic stress (ACE score of 4 or greater) and G9920 for lower risk (ACE score of 0–3) — handle the billing. Providers complete a two-hour training, self-attest, and become eligible to bill. The payment is not available for patients 65 and older, or for those dually eligible for Medi-Cal and Medicare Part B.

Twenty-one months later, California went further. In October 2021, the state enacted SB 428, the ACEs Equity Act, mandating that commercial insurance plans regulated by California cover ACE screening for adults and children. The commercial mandate took effect in 2022. California became the first state to require both Medicaid and commercial payers to cover ACE screening as a distinct service.

The program is operating at scale. ACEs Aware’s 2019–2023 Progress Report states that between January 1, 2020 and March 31, 2023, providers conducted more than 2.3 million ACE screenings of approximately 1.5 million unique Medi-Cal members, generating more than $66 million in payments to clinics serving predominantly low-income communities. RAND’s 2025 research brief on the initiative, California’s ACEs Aware Initiative Has Made Substantial Early Progress, but Sustained Investment Is Needed, reports that ACE screening proved feasible and acceptable in California clinics, that clinicians were able to incorporate it into practice, and that sustained investment is required to continue scaling.

Whatever one thinks of California’s broader Medicaid model, this payment mechanism now has more than five years of operational history, claims data, and independent evaluation.

One tension running underneath this conversation deserves to be named directly. The clinical evidence that ACE screening as an intervention reliably improves health outcomes is not yet settled. The California Health Benefits Review Program’s analysis of SB 428 found limited or insufficient evidence on whether ACE screening changes health care utilization or outcomes. RAND’s 2025 evaluation describes substantial early progress but not conclusive effectiveness. The reimbursement question and the clinical-effectiveness question are separable, and they are being answered by different institutions on different timelines. This piece is about the reimbursement question; it does not depend on the clinical debate being settled, and it should not be read as a clinical endorsement.

The spread is documented

For most of the program’s first four years, the question of whether the California payment mechanism would migrate was a leading indicator. As of 2025, the picture is more textured. One state has replicated the payment core and adapted the rest. One state has adopted the same payment mechanism in a very different Medicaid program. A third state has built an adjacent mechanism that uses ACE-related logic to expand coverage through different Medicaid authority. The pattern is not “California is being copied.” It is “ACE-related Medicaid policy is spreading through multiple architectures, with the California payment mechanism as the most prominent of them.”

New York implemented ACE screening reimbursement in phases beginning in 2024. New York Medicaid launched pediatric ACE screening reimbursement effective January 1, 2024 for fee-for-service and April 1, 2024 for Medicaid managed care, then expanded to include a one-time adult screening (ages 21 to 65), effective October 1, 2024 for fee-for-service and January 1, 2025 for managed care. The New York State Department of Health Medicaid program reimburses providers $29 per screen — the same rate California uses — with the same two HCPCS codes (G9919 and G9920) and the same general structure. Annual screening is covered for Medicaid members up to age 21; one lifetime screening is covered for members ages 21 through 65. Providers must have appropriate training and experience in ACE screening and trauma-informed care. The September 2024 Medicaid Update distinguished effective dates for fee-for-service and managed care implementation. The February 2025 Dear Colleague letter from the State Health Commissioner makes explicit the connection between ACE screening and downstream mental health outcomes that the rest of this piece will return to.

The fact that this is New York specifically matters. New York runs the second-largest state Medicaid program in the country, and it is a large, administratively complex Medicaid program outside California. Its Department of Health adopted the core elements of California’s payment architecture: the $29 payment amount, the same two HCPCS codes, and the same basic age and frequency structure. Two elements differ. New York does not replicate California’s training-attestation prerequisite; it requires only that the screening provider be licensed, or supervised by a licensed enrolled provider, and have appropriate training and experience in ACE screening and trauma-informed care. New York also does not mandate a specific instrument. It requires a research-based tool and names PEARLS, the ACE Questionnaire for Adults, the Center for Health Care Strategies modified ACEs questionnaire, and the CDC’s BRFSS ACE module as examples, leaving practices to adopt the tool that fits their population and workflow. California, by contrast, requires the PEARLS instrument for pediatric patients and the ACE Questionnaire for Adults for adult patients, and conditions payment on completing the Becoming ACEs Aware training and self-attesting to it. New York’s adoption demonstrates that the payment core of the California mechanism, the rate, the codes, and the age and frequency structure, is replicable in a Medicaid program operating under significantly different administrative conditions, and that a state can adopt that core while making its own choices about instruments and provider qualification.

Wyoming shows the payment core travels. It adopted a $29 ACE-screening payment for certified providers, although its implemented benefit is narrower: it applies to children with full Medicaid in the fee-for-service program. For FQHCs, RHCs, and IHS facilities, payment is included in the encounter rate rather than separately reimbursed.

Alaska represents an adjacent pathway. Alaska used data from its ALCANLink study, among other sources, to make the case to the Centers for Medicare and Medicaid Services for a Section 1115 demonstration providing community-based early intervention services to children and adolescents who have experienced four or more ACEs. According to the National Governors Association, Alaska is the first state to secure a demonstration of this kind. This is not a replication of California’s screening-payment architecture. It is a different Medicaid mechanism reaching a related population on the same upstream logic: that childhood adversity has reimbursable downstream consequences worth structuring Medicaid policy around.

The California Health Benefits Review Program’s 2021 analysis of SB 428 noted that “more than 35 states introduced legislation on ACEs in 2020,” and that since January 2019 at least 26 states had enacted or adopted legislation addressing childhood trauma, child adversity, toxic stress, or ACEs. Only about half a dozen states had gone as far as introducing coverage mandates for Medicaid or commercial insurers. The honest read of that data is that legislative attention has been widespread since 2020, while the payment mechanism itself has spread far more narrowly. New York validates the payment mechanism’s replicability; Wyoming shows the same mechanism operating in a very different state; Alaska shows the policy direction extending through different Medicaid authority. The pattern is a category of policy spreading, and reimbursement directors should treat further state activity as the base case, not the upside scenario.

Why this matters for hospital and health system reimbursement strategy

The $29 per-screen payment, taken on its own, is provider revenue rather than hospital DRG revenue. Hospital CFOs whose facilities don’t operate affiliated primary care practices may read the dollar amount and conclude the precedent is irrelevant to them. That conclusion is incomplete.

There are three implications worth tracking, in increasing order of strategic weight.

Revenue your providers may already be eligible for. If your system operates in California or New York and includes affiliated primary care, behavioral health, or pediatric practices, your providers may already be eligible to bill for ACE screenings and may not be doing so. The reasons vary: training or documentation requirements haven’t been met, workflow integration hasn’t happened, the screening tool isn’t in the EHR template, or no one has translated the eligibility into a billing workflow. At $29 per screen across an eligible patient panel, this is recurring revenue. Modest per encounter, but compounding when added to existing well-visit and behavioral health workflows. One carve-out belongs in this calculation. In New York, ACEs screening is included within the prospective payment system primary care rate for Federally Qualified Health Centers, so FQHC encounters generate no separate $29.

California FQHCs and RHCs may receive the applicable PPS or APM visit payment plus a separate $29 trauma-screening supplemental incentive payment. IHS-MOA facilities likewise may receive the supplemental payment in addition to the applicable all-inclusive visit payment. The precise treatment of other clinic categories should be confirmed under their applicable Medi-Cal methodology before excluding them from the revenue calculation.

Contract implications when your state follows California or New York. When a state Medicaid program adds an ACE screening benefit, several questions cascade into existing managed care contracts. How does the directed payment flow from the managed care plan to the network provider? What training requirements does the plan impose, and who covers the cost of compliance? How is screening integrated with existing well-visit codes and behavioral health workflows? What documentation standard must be met for the payment to be defensible against audit? California’s All Plan Letter 23-017, dated June 13, 2023, is the operational template that has now been functionally replicated in New York. Health systems that have done this contract work in advance of state adoption are in a stronger negotiating position than those that respond after the fact.

Commercial payer follow-through. This is the harder strategic question. California’s SB 428 is the more disruptive precedent because it set up the pattern of state-mandated commercial coverage years ahead of any analogous federal action. The dynamic to track is not only whether commercial mandates spread, but how they are structured if they do. California’s bill required commercial coverage but left latitude on whether the screening is separately reimbursed or bundled into the office visit. That latitude is where the contract negotiation happens, and reimbursement directors who haven’t surfaced the question with their commercial payers are likely to discover the answer in the form of a contract amendment they didn’t negotiate.

There is also a related implication for value-based contracts that this piece will note briefly and return to in a future article.

When ACE screening prompts further clinical evaluation that independently supports an active, risk-adjustment-eligible diagnosis under the governing model, the resulting documentation may have separate reimbursement consequences under Medicare Advantage or an applicable ACO arrangement. The ACE screen itself does not establish the diagnosis or determine HCC eligibility.

That is a separate argument with its own mechanics, and it deserves its own analysis.

What to do now

Six concrete actions worth considering before the next contracting cycle.

1. If your system operates in California or New York,audit whether your eligible network providers are billing for ACE screenings. The prerequisites differ by state. In California, confirm that clinicians have completed the Becoming ACEs Aware training and self-attested, since payment depends on it. In New York, confirm that the screening provider is licensed or appropriately supervised, that a research-based tool is documented, and that claims carry G9919 or G9920 with the U1 and U9 modifiers appearing consecutively in that order.
2. Review your Medicaid managed care contractsfor language addressing new screening benefits and how directed payments flow from the plan to the provider. The California APL 23-017 structure is the operational template that other states are now adopting. If your contracts don’t anticipate this pattern, they will be silent on it when your state moves.
3. Map your patient population by state of residenceif you operate across state lines. The state with the most aggressive payment mechanism may not be your largest patient state, but commercial contracts often follow the most aggressive state’s rules for that book of business.
4. Track state legislative activityon ACE-related Medicaid and commercial coverage. Government affairs and reimbursement teams should be in the same room on this; the pattern of state activity moves faster than annual contracting cycles.
5. Engage your behavioral health and primary care service lines on training infrastructure.California conditions billing eligibility on a provider-level training attestation; the Becoming ACEs Aware course is two hours and free. New York sets a competence expectation rather than an attestation requirement. States adopting this benefit may choose either model, and the difference matters operationally: an attestation requirement creates a discrete compliance step that can be completed in advance, while a competence standard shifts the burden to documentation and supervision.
6. Coordinate with your contracting team on commercial payer language.California’s SB 428 left latitude on whether screening is separately reimbursed or bundled. Your network agreements either address this question or they don’t. The negotiation is easier before the mandate than after.

Closing

May is Mental Health Awareness Month because the public health argument for paying attention to mental health is well-established. The reimbursement argument has been quieter. What California started in 2020, what Wyoming adopted, and what New York adopted in phases beginning in 2024 is a payment mechanism that operationalizes the upstream-mental-health conversation at the claim level — one completed screen, one compliant claim, and one paid encounter at a time.

The question for hospital and health system reimbursement directors is not whether to support trauma screening as a clinical matter. That conversation belongs to clinicians and to public health, and it is genuinely unsettled. The question is whether your reimbursement infrastructure — your contracts, your training compliance, your coding workflows, your commercial payer language — is positioned to absorb a payment mechanism that is no longer hypothetical and no longer confined to a single state.

The precedent is operating at scale. The spread is documented through multiple architectures. The infrastructure work is the part you control.

Sources provided upon request.